logo
Plus   Neg
Share
Email

Junshi And AstraZeneca Collaborate To Commercialize Toripalimab In China

Junshi Biosciences said it will grant AstraZeneca the exclusive promotion right of toripalimab in mainland China for the urothelial carcinoma indications to be approved subsequently for marketing and the exclusive promotion right for all indications approved and to be approved in non-core areas.

Junshi noted that it will continue to be responsible for the promotion of other indications approved and to be approved excluding urothelial carcinoma indications in core areas.

Junshi Biosciences and AstraZeneca will continue to explore overseas business collaboration including the emerging markets and actively explore the possibility of expanding the depth and breadth of future collaborations.

Toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing in China. More than thirty company-sponsored clinical studies covering more than fifteen indications have been conducted globally, including in China and the United States.

On 17 December 2018, Toripalimab obtained a conditional approval from the the National Medical Products Administration for the second-line treatment of unresectable or metastatic melanoma. Toripalimab was included in the 2019 and 2020 Guidelines of Chinese Society of Clinical Oncology for the Diagnosis and Treatment of Melanoma.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Johnson & Johnson's (JNJ) Covid-19 vaccine is expected to be back on track as early as this weekend as a decision is expected after the advisory panel meeting of the U.S. Centers for Disease Control and Prevention (CDC) slated on April 23, according to Dr. Anthony Fauci, the chief medical adviser to President Joe Biden. MK-4482, the experimental antiviral drug for COVID-19, showed promise to prevent and treat SARS-CoV-2 infection in hamster study, according to the scientists of National Institutes of Health or NIH. The drug significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection. MK-4482, delivered orally, is now in Phase 2 and 3 human clinical studies. Beverages giant Coca-Cola reported a 19 percent decline in profit for the second quarter from last year as a revenue growth of 5 percent and improved margins were offset by higher income taxes and interest expense. However, adjusted earnings per share and revenues topped analysts' expectations. The company also maintained its adjusted earnings and organic revenue growth outlook for fiscal 2021.
Follow RTT